Skip to main content

Advertisement

Figure 4 | BMC Cancer

Figure 4

From: Integrated genomics of ovarian xenograft tumor progression and chemotherapy response

Figure 4

Rosiglitazone reduces cisplatin and MT19c efficacy in SKOV-3. A. PPARγ network enriched in MT19c treated tumors. Ingenuity Pathway Analysis (IPA) of significantly up and down MT19c (Fold change > 1.4, p < 0.05) regulated genes comparing 16 day treated and naïve tumors identifies a network including PPARγ including PPARγ itself. Red indicates stimulated by MT19c and green indicates down regulation by MT19c. B. Addition of 10 μM Rosiglitazone increases the number of viable SKOV-3 cells when treated with MT19c (left panel) in a dose dependent manner (right panel). The number of viable cells was determined by a modified MTT assay using Wst-1. The y-axis represents percent of viable cells normalized to DMSO treated cells. Error bars represent standard deviation. * indicates p < 0.05 from a Student's t-test comparing MT19c treated and Rosiglitazone-MT19c treated cells. 10 μm Rosiglitazone has a range of effects on the NCI-60 panel of six ovarian cancer cell lines. Viability effects of Rosiglitazone in with cisplatin. - indicates < 20% decrease in number viable cells, - - indicates > 20% decrease in number viable cells, + indicates < 20% increase in number viable cells, + + indicates > 20% increase in number viable cells, o indicates no change in number of viable cells. C. Insulin centered network identified by IPA. Red indicates stimulated by MT19c and green indicates down regulation by MT19c. Ingenuity Pathway Analysis (IPA) of significantly up and down MT19c (Fold change > 1.4, p < 0.05) regulated genes comparing 16 day treated and naïve tumors identifies a network centered around insulin regulation.

Back to article page